Latest From William Masters
Sweden-based Elicera Therapeutics is developing next-generation oncolytic viruses and “fourth-generation” CAR-T cells. CEO Jamal El-Mosleh sat down with In Vivo ahead of the company’s IPO.
A selection of articles you might have missed from May 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Market Snapshot: The ulcerative colitis market looks set to experience strong pricing pressure over the next three to five years, with leading players losing exclusivity for their drugs and a flood of novel entrants set to hit the market.
Indian firm Alembic Pharmaceuticals discussed the challenges ahead for its US generics business while revealing a dramatic uptick in non-US overseas markets during its FY2021 financial earnings call.
Following early investor conversations, Laevoroc Oncology has split its leading products into three independent subsidiaries to off-set risk and provide greater choice to future partners. While there is no underlying platform technology, CEO Thomas Mehrling believes the subsidiaries all include potential “game-changing medicines.”